13S158: Abstracts: Spondyloarthritis Including PsA – Treatment II: PsA (1597–1602)

Abstract Moderator(s)

• CR

  Christopher Ritchlin, MD, MPH

  University of Rochester Medical Center
  Canandaigua, NY, United States

  Disclosure(s): AbbVie/Abbott: Consultant (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing); Gilead: Consultant (Ongoing); Janssen: Consultant (Ongoing); Novartis: Consultant (Ongoing); Pfizer: Consultant (Ongoing); Sanofi Pasteur Biologics LLC: Consultant (Ongoing); UCB: Consultant (Ongoing)
• 

  Victoria Navarro-Compán, MD

  La Paz University Hospital
  Madrid, Spain

  Disclosure(s): AbbVie: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Grant/Research Support (Terminated), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Eli Lilly: Advisor or Review Panel Member (Terminated), Consultant (Terminated), Grant/Research Support (Terminated), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Janssen: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Novartis: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Pfizer: Advisor or Review Panel Member (Terminated), Consultant (Terminated), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Roche: Grant/Research Support (Terminated); UCB: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

Oral abstract session.

Presentations:

• 3:00 PM – 3:10 PM Eastern Time

  Achievement of Different Treatment Targets with Izokibep Demonstrates Efficacy Benefits in Patients with Active Psoriatic Arthritis: Results from a 16-Week Randomized, Placebo-Controlled Phase 2 Clinical Trial
  

  Presenting Author: Frank Behrens, MD – Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Germany
• 3:10 PM – 3:15 PM Eastern Time

  Q&A
  
• 3:15 PM – 3:25 PM Eastern Time

  Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
  

  Presenting Author: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
• 3:25 PM – 3:30 PM Eastern Time

  Q&A
  
• 3:30 PM – 3:40 PM Eastern Time

  Bimekizumab Treatment in Patients with Active Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors: 16-Week Efficacy and Safety from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
  

  Presenting Author: Joseph F. Merola, MD, MSc – Harvard Medical School, Brigham and Women's Hospital
• 3:40 PM – 3:45 PM Eastern Time

  Q&A
  
• 3:45 PM – 3:55 PM Eastern Time

  The Impact of Second-Line Therapeutic on Disease Control After Discontinuation of First Line TNF Inhibitor in Patients with PsA: Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
  

  Presenting Author: Alexis Ogdie, MD – University of Pennsylvania
• 3:55 PM – 4:00 PM Eastern Time

  Q&A
  
• 4:00 PM – 4:10 PM Eastern Time

  Female Psoriatic Arthritis Patients Show Differences in Treatment Response to IL12/23 Inhibition in Combination with or Without MTX Compared to Male – Results from a Multicenter Investigator-initiated Randomized Placebo-controlled Clinical Trial
  

  Presenting Author: Michaela Koehm, MD – Rheumatology Goethe-University Frankfurt
• 4:10 PM – 4:15 PM Eastern Time

  Q&A
  
• 4:15 PM – 4:25 PM Eastern Time

  Fibroblast Activation Protein (FAP) PET-CT for Depicting Inflammatory Joint Damage in Patients with Psoriatic Arthritis
  

  Presenting Author: Andreas Ramming, MD – University Hospital Erlangen
• 4:25 PM – 4:30 PM Eastern Time

  Q&A